Promising examples of immunotherapy include canakinumab, an IL-1B antibody which has demonstrated effects in reinstating hematopoietic balance in SF3B1 mutated MDS in vitro models [42]. This evidence concerns the gene IL1B and myelodysplastic syndrome.